Table 1. Baseline characteristics, tumor classification, and status between the treatment groups.
| Characteristics | IBI305, N=221 | Bevacizumab, N=220 | Total, N=441 |
|---|---|---|---|
| Age (years) (mean ± SD) | 57.6±8.69 | 57.2±9.28 | 57.4±8.98 |
| <60 (n, %) | 119 (53.8) | 118 (53.6) | 237 (53.7) |
| ≥60 (n, %) | 102 (46.2) | 102 (46.4) | 204 (46.3) |
| Weight (mean ± SD) | 62.2±10.8 | 62.1±10.3 | 62.2±10.6 |
| Gender | |||
| Male (n, %) | 142 (64.3) | 137 (62.3) | 279 (63.3) |
| Female (n, %) | 79 (35.7) | 83 (37.7) | 162 (36.7) |
| Nationality | |||
| Han (n, %) | 217 (98.2) | 211 (95.9) | 428 (97.1) |
| Others (n, %) | 4 (1.8) | 9 (4.1) | 13 (2.9) |
| Smoking status (n, %) | |||
| Never | 102 (46.2) | 109 (49.5) | 211 (47.8) |
| Former | 78 (35.3) | 60 (27.3) | 138 (31.3) |
| Current | 41 (18.6) | 51 (23.2) | 92 (20.9) |
| ECOG | |||
| 0 (n, %) | 55 (24.9) | 55 (25.0) | 110 (24.9) |
| 1 (n, %) | 166 (75.1) | 165 (75.0) | 331 (75.1) |
| Histology (mean ± SD) | 219 (2) | 217 (3) | 436 (5) |
| Adenocarcinoma (n, %) | 215 (97.3) | 212 (96.4) | 427 (96.8) |
| Bronchioloalveolar adenocarcinoma (n, %) | 3 (1.4) | 3 (1.4) | 6 (1.4) |
| Large-cell carcinoma (n, %) | 0 | 1 (0.5) | 1 (0.2) |
| Mixed adenocarcinoma (n, %) | 1 (0.5) | 1 (0.5) | 2 (0.5) |
| Other (n, %) | 2 (0.9) | 3 (1.4) | 5 (1.1) |
| Disease stage | |||
| IIIB (n, %) | 25 (11.3) | 32 (14.5) | 57 (12.9) |
| IV (n, %) | 196 (88.7) | 188 (85.5) | 384 (87.1) |
| EGFR status | |||
| Wild-type (n, %) | 215 (97.3) | 217 (98.6) | 432 (98.0) |
| Unknown (n, %) | 6 (2.7) | 3 (1.4) | 9 (2.0) |
SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.